Skip to main content
Premium Trial:

Request an Annual Quote

NanoInk Division Launches Contract Research Service

Premium

This story originally ran on Sept. 9.

NanoInk this week said that its NanoBioDiscovery division has launched its contract research program.

The contract services will use NanoBioDiscovery's Dip Pen Nanolithography technology, which was developed by Chad Mirkin, a professor of chemistry at Northwestern University, and a founder of NanoInk.

The services being provided include custom assay development, analysis projects, protein profiling, and custom array printing, NanoBioDiscovery said in a statement. The division was formed in December as NanoInk shifted away from the semiconductor business, the original target market for its DPN technology, to the life science market. In March, a company official told ProteoMonitor that an instrument based on the technology, as well as its service business, would be launched during the third quarter [See PM 03/19/09].

The instrument has yet to launch, and a spokeswoman for NanoInk said this week the company had no update on when it will.

The DPN technology is a method of nanofabrication in which a sharp probe spots a biomolecule onto a surface, such as a glass slide. Data generated from an assay developed with the technology is similar to what can be achieved with an ELISA or other immunoassays, but because the DPN technology can precisely place the molecule on the surface, the donut-hole and coffee-ring effect seen with other spotting techniques can be avoided, leading to higher quality arrays, Bruce Dudzik, NanoInk's senior director for business development, said in March.

This week, NanoInk, based in Skokie, Ill., said that the DPN technology can deposit "highly reproducible, submicron protein features in one sub-array and [pattern] as many as 96 sub-arrays per slide."

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.